Biosimilar Coverage By The VA — What You Need To Know
Biosimilar Coverage By The VA — What You Need To Know

Merck’s recent announcement that its infliximab biosimilar, Renflexis, was awarded a U.S. Department of Veterans Affairs (VA) national contract has sparked curiosity about the potential influence this might have on biosimilar adoption and formulary preference in the rest of the market. Renflexis was determined to be the lowest-priced infliximab proposed under a competitive solicitation and, as such, was awarded preferred use as the only infliximab option covered on the VA National Formulary (VANF).

  • Express Scripts New Flex Formulary: Biosimilar Friend Or Foe?
    Express Scripts New Flex Formulary: Biosimilar Friend Or Foe?

    Though it’s much too early to say for sure, we will need to watch how this formulary impacts the brand vs. biosimilar landscape, and, in turn, the performance of biosimilars in the pharmacy reimbursement space.

  • West Coast Employers Eye Biosimilars
    West Coast Employers Eye Biosimilars

    One employer group expert provides a good look at the current relationships between employers and those assisting them with their healthcare decisions, as well as how the Pacific Business Group on Health, has set out to create a biosimilar educational and market push initiative.

  • An Inside Look: The Oncologist’s Perspective On Biosimilars
    An Inside Look: The Oncologist’s Perspective On Biosimilars

    Biosimilar Development regularly discusses educational strategies and biosimilar market access strategies implemented around the world. However, one perspective that deserves more attention (on this site and elsewhere) is that of oncologists. After all, these are the experts on the front lines, experiencing manufacturers’ education strategies and influencing biosimilar uptake.

  • How Will Trump’s New FTC/DOJ Reporting Requirements Impact Biosimilars?
    How Will Trump’s New FTC/DOJ Reporting Requirements Impact Biosimilars?

    On Oct. 10, 2018, President Trump signed into law the Patient Right to Know Drug Prices Act, which, among other things, requires that certain biosimilar applicants and reference product sponsors involved in patent disputes file their settlement agreements with the FTC and the DOJ. This article summarizes the key provisions of the new law and discusses its limitations.

  • Reaching Employers: How Biosimilar Makers Can Close The Gap
    Reaching Employers: How Biosimilar Makers Can Close The Gap

    In addition to learning about the biosimilar-related activities National Alliance of Healthcare Purchasers Coalition has implemented recently, I picked one expert's brain about which educational strategies would best reach employers during this age when the entire U.S. healthcare system is under the microscope.

  • Biosimilars Vs. AbbVie So Far: “Humirapocalypse” Or Illusion?
    Biosimilars Vs. AbbVie So Far: “Humirapocalypse” Or Illusion?

    Humira is said to have recently won a national tender in the EU thanks to a startling 80 percent discount to the pre-biosimilar price tag. However, as the dust clears from the initial news, things are less clear-cut than they may have appeared.

  • If Four-Letter Suffixes Aren’t Used In Biosimilar Tracking, What Use Are They?
    If Four-Letter Suffixes Aren’t Used In Biosimilar Tracking, What Use Are They?

    The implementation of the Biologics Price Competition and Innovation Act1 (BPCIA) raised a number of critical issues for manufacturers, payers, and prescribers. These include the big-picture questions of extrapolation of indications, interchangeability, and a radical new approach to evaluating the comparability of these drugs to their reference biologics, as well as approving them.

  • U.S. Biosimilar Progress: Are We Getting Ahead Of Ourselves?
    U.S. Biosimilar Progress: Are We Getting Ahead Of Ourselves?

    Rather than focusing on whether the market has a solid basis to survive, one expert presents some interesting perspectives on the need for a more measured perspective on the market’s financial growth, as well as on the current role of biosimilar competition and differentiation.

  • Mylan’s Pegfilgrastim Journey: Retracing Its Steps Towards Fulphila’s Launch
    Mylan’s Pegfilgrastim Journey: Retracing Its Steps Towards Fulphila’s Launch

    During our conversation, Kokino and I walked through the steps Mylan took to establish this foundation, as well as how the company’s overseas biosimilar experiences influenced its global — including the U.S. — biosimilar launch strategy.  

More Biosimilar editorial...

BIOSIMILAR INSIGHTS

More From Biosimilar...

TRAINING COURSES

Trade and Channel Strategies 2018 December 11 - 12, 2018
Philadelphia, PA)
Specialty Product Data Strategies December 12, 2018
Philadelpia, PA)
Copay Accumulator Summit December 13, 2018
Philadelphia, PA)
14th Annual Biosimilars Summit January 22 - 23, 2019
Alexandria, VA)
Reimbursement and Contracting January 23 - 24, 2019
Philadelphia, PA)
6th Annual Reimbursement and Contracting January 23 - 24, 2019
Philadelphia, PA)
Patients Registries & Real World Evidence Summit January 30 - 31, 2019
Miami, FL)
PAP 2019 March 5 - 6, 2019
Baltimore, MD)
IVT's Statistics in Validation March 6 - 7, 2019
Philadelphia, PA)
Medical Device Validation Week March 12 - 14, 2019
Minneapolis, MN)
More Upcoming Courses
Anna Rose Welch article header

 EVENTS

Trade and Channel Strategies 2018 December 11 - 12, 2018
Philadelphia, PA)
Specialty Product Data Strategies December 12, 2018
Philadelpia, PA)
Copay Accumulator Summit December 13, 2018
Philadelphia, PA)
14th Annual Biosimilars Summit January 22 - 23, 2019
Alexandria, VA)
Reimbursement and Contracting January 23 - 24, 2019
Philadelphia, PA)

LIFE SCIENCE EVENTS

Trade and Channel Strategies 2018 December 11 - 12, 2018
Philadelphia, PA
Specialty Product Data Strategies December 12, 2018
Philadelpia, PA
Copay Accumulator Summit December 13, 2018
Philadelphia, PA
14th Annual Biosimilars Summit January 22 - 23, 2019
Alexandria, VA
Reimbursement and Contracting January 23 - 24, 2019
Philadelphia, PA
More Events...

LIFE SCIENCE INDUSTRY EVENTS

Trade and Channel Strategies 2018 December 11 - 12, 2018
Philadelphia, PA
Specialty Product Data Strategies December 12, 2018
Philadelpia, PA
Copay Accumulator Summit December 13, 2018
Philadelphia, PA
14th Annual Biosimilars Summit January 22 - 23, 2019
Alexandria, VA
Reimbursement and Contracting January 23 - 24, 2019
Philadelphia, PA
More Industry Events

ABOUT BIOSIMILAR DEVELOPMENT

Biosimilar Development is dedicated to presenting technical information, thought leadership, and commentary for the biosimilar development and manufacturing community. On this site, users will find exclusive and actionable content on the industry trends and challenges affecting the emerging biosimilars market. Browse our articles, case studies, and white papers on topics related to biosimilar development, manufacturing, quality, distribution, FDA guidance, BPCIA, global markets, government regulations, and intellectual property.

Biosimilar Development is part of the Life Science Connect media group, which strives to facilitate connections and foster collaborations in pharmaceutical development to find ways to get more life-saving and life-improving therapies to market. Connect, Collaborate, Contribute.